Urology industry veteran Steve Blum joins Board of Directors; Axonics co-founder and former CEO Raymond W. Cohen named Senior Advisor
MILWAUKEE, Nov. 17, 2026 /PRNewswire/ -- Rivermark Medical, a medical device company developing innovative treatments for benign prostatic hyperplasia (BPH), today announced the completion of enrollment in its RAPID III pivotal clinical study of the FloStent™ System.
Rivermark also named Steve Blum an independent member of its Board of Directors and Raymond W. Cohen as Senior Advisor.
"Completing enrollment in RAPID III is an important milestone for Rivermark, and we are grateful to the patients, investigators and clinical teams who made it possible," said Adam Kadlec, M.D., co-founder, president and CEO of Rivermark Medical. "Steve's experience leading urology businesses and Ray's track record of building medtech companies will help us plan for the next stage of Rivermark's development while our clinical team continues patient follow-up."
About RAPID III and FloStent
RAPID III is a prospective, multicenter, randomized, double-blind study evaluating the safety and effectiveness of FloStent in men with lower urinary tract symptoms caused by BPH. The study randomized 216 men with BPH, and the key endpoint is the change in International Prostate Symptom Score (IPSS). Rivermark will continue patient follow-up and data collection in preparation for a Premarket Approval (PMA) submission to the U.S. Food and Drug Administration.
FloStent is an investigational, minimally invasive implant designed to rapidly relieve BPH-related urinary symptoms without tissue alteration. The system integrates with a standard flexible cystoscope and is designed for placement during a routine outpatient cystoscopy without additional capital equipment, as well as adjustment or retrieval using standard urological tools to preserve future treatment options.
About Blum
Blum brings decades of medical device leadership experience. Most recently, he served as President and Senior Vice President of Coloplast's global Interventional Urology business, where he led the Men's Health, Endosurgery and Women's Health divisions. Before Coloplast, he served as Global President and General Manager of Female Urology at American Medical Systems, overseeing operations in 75 countries.
"Rivermark is addressing a real gap in BPH treatment with a therapy designed to fit how urologists already work," said Blum. "FloStent builds on familiar instruments and techniques, an important consideration when introducing a new treatment into clinical practice."
About Cohen
Cohen has more than 40 years of experience in the life sciences industry. He co-founded Axonics, Inc., took the company public in 2018 and led it through its $3.7 billion acquisition by Boston Scientific in 2024. Previously, he served as CEO of Vessix Vascular, acquired by Boston Scientific in 2012, and as chairman and CEO of Cardiac Science. He currently serves on the boards of several medical technology companies.
"Completing enrollment gives Rivermark a clear focus: following patients and building the evidence needed for its regulatory submission," said Cohen. "Alongside that work, there is an opportunity to prepare the business for commercialization. I look forward to supporting Adam and the team as they set those priorities and build the capabilities they will need."
About BPH and Rivermark Medical
BPH affects nearly 40 million men in the United States and more than 500 million men worldwide. Although not life-threatening, the condition can significantly affect quality of life. Existing therapies may require trade-offs between symptom relief, invasiveness and recovery time.
Rivermark Medical develops minimally invasive therapies for BPH, with a focus on patient choice and ease of use for physicians. Led and co-founded by practicing urologist Adam Kadlec, M.D., the company creates solutions grounded in real-world clinical needs. For more information, visit www.rivermarkmedical.com
CAUTION: Investigational Device
The FloStent™ System is limited by Federal (or United States) law to investigational use.
SOURCE Rivermark Medical

Share this article